In an effort to make relevant clinical trials more accessible to patients, the Hemophilia Federation of America (HFA) has launched a clinical trial finder website. The trial finder, powered by Citeline Connect, links directly from the HFA website. With the HFA trial finder, visitors can search across all clinical trials, regardless of sponsor.
NEW YORK, June 15, 2023 /PRNewswire-PRWeb/ -- In an effort to make relevant clinical trials more accessible to patients, the Hemophilia Federation of America (HFA) has launched a clinical trial finder website. The trial finder, powered by Citeline Connect, links directly from the HFA website.
Globally, more than 400,000 people have hemophilia and other bleeding disorders. As there is no cure for these diseases, patients and caregivers seek reliable information on treatments in development.
With the HFA trial finder, visitors can search across all clinical trials, regardless of sponsor. Searches can be filtered by condition — including various types of hemophilia, hepatitis, factor vii deficiency, platelet disorder and Von Willebrand disease — study status, study phase, age and sex of participant. Visitors also can search by keyword or geographic location. Search results show study details: the name of the drug, dates of the study, the requirements, known as eligibility or inclusion/exclusion criteria, the study's focus, the protocol summary, and trial locations.
Clinical trial sponsors and patient advocacy groups rely on Citeline Connect to streamline journeys into clinical trials with solutions made for patients, with patients. Built on a globally compliant data analytics platform, Citeline Connect's end-to-end digital engagement experiences and multichannel recruitment programs prevent patient drop-off and reduce the burden of enrollment for all stakeholders.
"Citeline Connect is honored to support HFA in its mission to provide patient-centered tools and resources around clinical trials for families impacted by rare bleeding disorders," said David Laky, Global Head of Clinical and Regulatory at Citeline. "The new HFA trial finder website simplifies how their community members can discover and learn about clinical research as a care option, and represents an incremental step closer to bringing breakthrough medicines to patients."
"Patients and families have asked for a way to easily search for clinical trials, and Hemophilia Federation of America is excited to offer this new resource that will empower patients and their families to search for available clinical trials and work with their care team to determine eligibility," said Dan Kelsey, President and CEO of HFA.
For more information, visit https://trials.hemophiliafed.org/search-results. For more information on Citeline Connect, visit https://pages.pharmaintelligence.informa.com/Partner-Connect-100-Sponsor.
Citeline, a Norstella company, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory-related decisions and create real-world opportunities for growth.
Citeline's global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. For more information on one of the world's most trusted health science partners, visit Citeline.
About the Hemophilia Federation of America
Hemophilia Federation of America is a patient education, services and advocacy organization serving the rare bleeding disorders community. HFA focuses on the bleeding disorders patient and caregiver community. More than 50 member organizations across the country utilize HFA's collaborative federation to strengthen community support and awareness, develop effective local organizations, and implement valuable programs.
SOURCE Hemophilia Federation of America